Genetic Determinants of Hemodynamic Response to Esmolol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01388036|
Recruitment Status : Unknown
Verified July 2011 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : July 6, 2011
Last Update Posted : July 6, 2011
Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.
The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.
|Condition or disease||Intervention/treatment||Phase|
|Decrease in Heart Rate Below Baseline Value||Drug: esmolol||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||May 2015|
Experimental: esmolol infusion
infusion of esmolol during rest and exercise
consecutive infusions of esmolol and normal saline (placebo)
- Change in heart rate during exercise [ Time Frame: 3 hours ]continous measurement of heart rate
- change in systolic blood pressure during exercise [ Time Frame: 3 hours ]measurement of systolic blood pressure every 5 minutes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388036
|Contact: Mordechai Muszkat, MD||972-2-6777111 ext email@example.com|
|Hadassah Hebrew University Medical Center||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Mordechai Muszkat, MD 972-2-6777111 ext 73793 firstname.lastname@example.org|
|Principal Investigator: Mordechai Muszkat, MD|